Evidence map›Paper›PMID 39416057›Full record

ArticlebioRxiv : the preprint server for biology2024

RIPK2 is crucial for the microglial inflammatory response to bacterial muramyl dipeptide but not to lipopolysaccharide.

Changjun Yang, Maria Carolina Machado da Silva, John A Howell, Jonathan Larochelle, Lei Liu, Rachel E Gunraj, Antônio Carlos Pinheiro de Oliveira, Eduardo Candelario-Jalil

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Changjun YangDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Maria Carolina Machado da SilvaDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
John A HowellDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Jonathan LarochelleDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Lei LiuDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Rachel E GunrajDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Antônio Carlos Pinheiro de OliveiraDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Eduardo Candelario-JalilDepartment of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-3631-1989

Funding

Role of RIPK2 in the neuroinflammatory response to ischemic strokeR01NS129136 · NINDS · UNIVERSITY OF FLORIDA · PI Eduardo Jesus Candelario-Jalil · 2023 to 2026
$1.6M
American Heart Association-American Stroke Association 971058NINDS NIH HHS R01 NS129136
6 · The paper itself

Abstract

Receptor-interacting serine/threonine protein kinase 2 (RIPK2) is a kinase that plays an essential role in the modulation of innate and adaptive immune responses. As a downstream signaling molecule for nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs), it is implicated in the signaling triggered by recognition of microbe-associated molecular patterns by NOD1/2 and TLRs. Upon activation of these innate immune receptors, RIPK2 mediates the release of pro-inflammatory factors by activating mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-κB). However, whether RIPK2 is essential for downstream inflammatory signaling following the activation of NOD1/2, TLRs, or both remains controversial. In this study, we examined the role of RIPK2 in NOD2-and TLR4-dependent signaling cascades following stimulation of microglial cells with bacterial muramyl dipeptide (MDP), a NOD2 agonist, or lipopolysaccharide (LPS), a TLR4 agonist. We utilized a highly specific proteolysis targeting chimera (PROTAC) molecule, GSK3728857A, and found dramatic degradation of RIPK2 in a concentration- and time-dependent manner. Importantly, the PROTAC completely abolished MDP-induced increases in iNOS and COX-2 protein levels and pro-inflammatory gene transcription of

Indexed as

inflammatory responselipopolysaccharidemicrogliamitogen-activated protein kinasemuramyl dipeptidenuclear factor-kappa Bnucleotide-binding oligomerization domain-like receptorreceptor-interacting serine/threonine protein kinase 2Toll-like receptor

Identifiers

PMID39416057
PMCPMC11482783

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.